is zepbound glp 1 FDA approval for (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Zepbound Effective for Weight Loss

Rocha M, Diaz-Morales N, Rovira-Llopis S, et al

Based on studies in non-diabetics with obesity, or overweight plus a weight-related condition, with diet and exercise

Lucey M, Ashik T, Marzook A, et al

Cardiovascular Safety Benefits One of the most encouraging aspects of GLP-1 safety research involves heart health

In addition, Lilly has said it should be able to scale up production of orforglipron without the same supply constraints that it's faced with Mounjaro and Zepbound

Medications that activate both GLP-1 and GIP receptors produce even better results, with tirzepatide showing 22.5% average weight loss compared to semaglutides 14.9%